Drugs / CMVPepVax
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01588015 | Oct 2012 → Feb 2024 | B-cell adult acute lymphocytic leukemia, Burkitt lymphoma, MALT lymphoma, T-cell adult acute lymphocytic leukemia +34 | City of Hope Medical Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMVPepVax | “CMVPepVax is an investigational peptide vaccine designed to control CMV infection in HCT recipients seropositive for CMV by stimulating the expansion of T cell subsets that...” PMID 30562587 ↗ Dec 2018 |
| Route | Subcutaneous | “CMVPepVax was administered subcutaneously on days 28 and 56.” PMID 26853648 ↗ Dec 2015 |